Table 1 Characteristics of scleroderma patients and healthy individuals with ELISA measurement
Clinical characteristics (mean±s.e.m.) | SSc (n=46) | LSc (n=43) | Healthy individuals (n=46) |
|---|---|---|---|
Age (years) | 45.5±2.1 | 31.0±2.3 | 42.4±1.7 |
Gender | |||
Female | 40 | 38 | 36 |
Male | 6 | 5 | 10 |
Disease duration (years) | 5.6±0.7 | 6.9±0.8 | / |
Years from the onset of Raynaud’s phenomenon | 4.8±0.6 | / | / |
Modified Rodnan skin score (MRSS) | 8.1±1.0 | 2.3±0.4 | / |
Autoantibodies | |||
Anti-topoisomerase antibody | 24 (52.2%) | / | / |
Anti-centromere antibody | 7 (15.2%) | / | / |
Anti-U1RNP antibody | 7 (15.2%) | / | / |
Medication history | |||
Snow glycosides tablets alone | 11 (23.9%) | 29 (67.4%) | / |
Oral glucocorticoid alone | 5 (10.9%) | 4 (9.3%) | / |
Snow glycosides tablets and oral glucocorticoid | 25 (54.3%) | 5 (11.6%) | / |
Number of SSc patients with organ involvement | |||
Esophagus involvement | 28 | / | / |
Pulmonary fibrosis | 24 | / | / |
Arthritis/arthralgia | 21 | / | / |
Raynaud's phenomenon | 33 | / | / |
Heart involvement | 14 | / | / |
